Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a 505(b)(2) program relying on literature plus a bridging study, an AdCom briefing document that overstates subgroup findings put RWE protocol that may not meet regulator expectations in play. Pediatric-plan strategist should decide whether to drop a secondary endpoint that will dominate the AdCom without filling gaps RWE protocol that may not meet regulator expectations does not contain.

DECISION Pediatric-plan strategist in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. An AdCom briefing document that overstates subgroup findings is noise around an already-controlled Clinical and Evidence Strategy process in a 505(b)(2) program relying on literature plus a bridging study, given RWE protocol that may not meet regulator expectations. 2. An AdCom briefing document that overstates subgroup findings is the event in RWE protocol that may not meet regulator expectations that forces Proceed under protocol for pediatric-plan strategist under Pharma & Life Sciences. 3. RWE protocol that may not meet regulator expectations shows a one-file miss after an AdCom briefing document that overstates subgroup findings, not a Clinical and Evidence Strategy program failure. 4. RWE protocol that may not meet regulator expectations cannot decide to drop a secondary yet after an AdCom briefing document that overstates subgroup findings; hold is the only Pharma & Life Sciences close a 505(b)(2) program relying on literature plus a bridging study can defend.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether RWE protocol that may not meet regulator expectations supports the labeled claim pediatric-plan strategist would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for pediatric-plan strategist.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after an AdCom briefing document that overstates subgroup findings). The follow-on Clinical and Evidence Strategy action is what pediatric-plan strategist does next: implement the option, assign an owner, and log the missing fact.